APP and Down syndrome: To investigate early-onset AD in patients with Down syndrome, CRISPR-Cas9 was used to delete the supernumerary copy of APP in T21 lines and inducible CRISPRa to upregulate APP gene expression (Ovchinnikov et al., 2018).